## **Prostate 2023 Case Scenario**

45-year-old male who presented with abnormal DRE, nodule/mass on LT-hand side noted with normal seminal vesicle, with elevated PSA of 14.9 taken on 5/9/2021.

5/9/2021: Prostate core bx

1. Prostate, LT base: prostatic tissue with focal high grade prostatic intraepithelial neoplasia (HGPIN),
2. Prostate, LT mid: adenocarcinoma of prostate. GS= 7(4+3), involving 60% of tissue, 1 out of 2 cores involved by tumor,
3. Prostate, LT apex: adenocarcinoma of prostate. GS= 7(4+3), involving 90% of tissue, 2 out of 2 cores involved by tumor,
4. Prostate, RT base: benign prostatic tissue,
5. Prostate, RT mid: benign prostatic tissue,
6. Prostate RT apex: small fragment suspicious for prostatic adenocarcinoma:

8 cores total taken

5/10/21: MRI pelvis: Lesion in LT mid-gland to apex peripheral zone and transitional zone with features consistent with prostate cancer. No evidence of pelvic lymphadenopathy. No EPE and No SVI identified.

5/18/21: Robotic-assisted total radical prostatectomy

**Procedure:** Radical prostatectomy

**Histologic Type: A**denocarcinoma, mixed acinar and ductal type

**Histologic Grade**

**Grade Group and Gleason Score:** Grade group 2 (Gleason score 3 + 4)

**Percentage of Pattern 4 in Gleason Score 7:** 70%

**Percentage of Pattern 5:** 0%

**Tumor Quantitation:** Carcinoma present on 14 of 20 histologic

 sections

**Extraprostatic Extension (EPE):** Not identified

**Urinary Bladder Neck Invasion:** Not identified

**Seminal Vesicle Invasion:** Not identified

**Margins:** Negative for carcinoma

**Treatment Effect on carcinoma:** No known presurgical therapy

**Lymphovascular Invasion:** Not identified

**Regional Lymph Nodes:** No nodes submitted

**Additional Pathologic Findings:** High grade prostatic intraepithelial neoplasia

|  |
| --- |
| Worksheet |
| Primary Site |  |  |  | Clinical Grade |  |
| Histology |  |  |  | Pathological Grade |  |
| RLN pos  |  | RLN examined |  | Post Therapy Grade |  |
| Laterality |  |
| LVI |  |
| Tumor size clinical |  |
| Tumor size path |  |
| Tumor size summary |  |
| Stage Data items |
| AJCC Stage |
| Clinical T |  | Pathological T |  | Post-therapy T |  |
| cT Suffix |  | pT Suffix |  | pT Suffix |  |
| Clinical N |  | Pathological N |  | Post-therapy N |  |
| cN Suffix |  | pN Suffix |  | pN Suffix |  |
| Clinical M |  | Pathological M |  | Post-therapy M |  |
| Clinical Stage  |  | Pathological Stage |  | Post-therapy Stage |  |
|  |  |  |
| Summary Stage 2018  |  |
| *EOD Primary Tumor* |  |
| *EOD Lymph Regional Nodes* |  |
| *EOD Mets* |  |
| *Prostate Pathologic Extension* |  |
| SSDI’s |
| Gleason Patterns Clinical |  |
| Gleason Patterns Pathological |  |
| Gleason Score Clinical |  |
| Gleason Score Pathological |  |
| Gleason Tertiary Pattern |  |
| Number of Cores Positive |  |
| Number of Cores Examined |  |
| PSA |  |
| Treatment  |
| Dx staging procedure |  |  |  |
| Surgery reason no rx |  |  |  |
| Surgical Approach at hospital |  |  |  |
| Surgery course |  |  |  |
| Surgery of primary site |  |  |  |
| Scope of RLN surgery |  |  |  |
| Surgery to other site |  |  |  |
| Cancer Status |  |  |  |